{
  "id": "migraine-with-aura",
  "title": "Migraine with Aura",
  "version": "1.1",
  "icd10": [
    "** G43.109 (Migraine with aura",
    "not intractable",
    "without status migrainosus)",
    "G43.101 (with status migrainosus)",
    "G43.119 (intractable",
    "without status migrainosus)",
    "G43.111 (intractable",
    "with status migrainosus)",
    "G43.409 (Hemiplegic migraine",
    "not intractable)",
    "G43.419 (Hemiplegic migraine",
    "intractable)"
  ],
  "scope": "** Diagnosis and management of migraine with typical aura (visual, sensory, language) and hemiplegic migraine. Focuses on outpatient management with acute care considerations. Covers differentiation from TIA/stroke, contraceptive counseling, and preventive therapy. Excludes migraine with brainstem aura (separate protocol) and retinal migraine.",
  "notes": [],
  "sections": {
    "Laboratory Workup": {
      "Essential/Core Labs": [
        {
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Rule out anemia, infection; baseline before treatment",
          "target": "Normal"
        },
        {
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Electrolyte abnormalities; renal function for medication dosing",
          "target": "Normal"
        },
        {
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Hypoglycemia can mimic aura; hyperglycemia raises stroke risk",
          "target": "70-180 mg/dL"
        },
        {
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "-",
          "rationale": "Coagulation screen if stroke consideration; before LP",
          "target": "Normal"
        },
        {
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Vascular risk assessment",
          "target": "<7% optimal"
        },
        {
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Vascular risk stratification",
          "target": "LDL <100 mg/dL"
        }
      ],
      "Extended Workup": [
        {
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Rule out GCA if age >50 with new visual symptoms",
          "target": "Normal"
        },
        {
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Thyroid dysfunction can trigger headache/aura-like symptoms",
          "target": "Normal (0.4-4.0 mIU/L)"
        },
        {
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Deficiency linked to migraine with aura specifically",
          "target": ">4.2 mg/dL"
        },
        {
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Elevated levels associated with migraine with aura and stroke",
          "target": "<15 μmol/L"
        },
        {
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Deficiency can elevate homocysteine; sensory symptoms",
          "target": "Normal"
        },
        {
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Deficiency associated with increased migraine frequency",
          "target": ">30 ng/mL"
        }
      ],
      "Rare/Specialized": [
        {
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "Thrombophilia workup if young stroke or recurrent prolonged aura",
          "target": "Negative"
        },
        {
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "Hereditary thrombophilia if recurrent aura or stroke-like events",
          "target": "Negative"
        },
        {
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "CNS lupus in atypical presentations",
          "target": "Negative"
        },
        {
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "Elevated homocysteine with aura",
          "target": "Wild type or heterozygous"
        },
        {
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "Hemiplegic migraine suspected; family history",
          "target": "Variant identified"
        },
        {
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "-",
          "rationale": "Rule out meningitis, SAH if atypical presentation",
          "target": "Normal; no xanthochromia"
        }
      ]
    },
    "Imaging & Studies": {
      "Essential/First-line": [
        {
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "First presentation with aura; rule out stroke/structural lesion",
          "target": "Normal; no acute infarct; no WMH concerning for vasculopathy",
          "contraindications": "MRI-incompatible devices"
        },
        {
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "-",
          "timing": "Acute presentation if MRI unavailable; rule out hemorrhage",
          "target": "No hemorrhage or mass",
          "contraindications": "Pregnancy (relative)"
        },
        {
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "First aura or prolonged aura to assess intracranial vessels",
          "target": "No stenosis, aneurysm, or dissection",
          "contraindications": "MRI contraindications"
        }
      ],
      "Extended": [
        {
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "Atypical features; persistent deficits; concern for mass",
          "target": "No enhancement; no mass",
          "contraindications": "Gadolinium allergy; severe renal impairment"
        },
        {
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "Suspected cervical dissection (neck pain, Horner syndrome)",
          "target": "No dissection",
          "contraindications": "MRI contraindications"
        },
        {
          "ED": "STAT",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "-",
          "timing": "Acute vascular imaging if MRI unavailable",
          "target": "No aneurysm, dissection, occlusion",
          "contraindications": "Contrast allergy; CKD (eGFR <30)"
        },
        {
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "Evaluate for PFO if recurrent aura or cryptogenic stroke history",
          "target": "No PFO; if present, assess shunt size",
          "contraindications": "None"
        }
      ],
      "Rare/Specialized": [
        {
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-",
          "timing": "Detailed cardiac source evaluation if TTE positive or high suspicion",
          "target": "No cardiac thrombus; characterize PFO",
          "contraindications": "Esophageal pathology"
        },
        {
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "EXT",
          "ICU": "-",
          "timing": "Prolonged aura to differentiate migrainous infarct from stroke",
          "target": "No DWI restriction",
          "contraindications": "MRI contraindications"
        },
        {
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "PFO screening; noninvasive alternative to TTE bubble",
          "target": "No right-to-left shunt",
          "contraindications": "Inadequate acoustic windows"
        },
        {
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "EXT",
          "ICU": "-",
          "timing": "Aura with altered consciousness; differentiate from seizure",
          "target": "No epileptiform activity",
          "contraindications": "None"
        }
      ]
    },
    "Treatment": {
      "Acute/Emergent": [
        {
          "item": "Ketorolac",
          "route": "IV/IM",
          "indication": "First-line acute migraine with aura in ED",
          "dosing": {
            "doseOptions": [
              {
                "text": "30 mg",
                "orderSentence": "Ketorolac 30 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "30 mg IV (15 mg if >65y, renal impairment, or <50 kg); max 5 days NSAIDs",
            "orderSentence": "Ketorolac 30 mg IV"
          },
          "contraindications": "Renal impairment (CrCl <30); active GI bleed; aspirin/NSAID allergy; third trimester",
          "monitoring": "Renal function if repeated dosing",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "-"
        },
        {
          "item": "Metoclopramide",
          "route": "IV",
          "indication": "Antiemetic with anti-migraine properties",
          "dosing": {
            "doseOptions": [
              {
                "text": "10 mg",
                "orderSentence": "Metoclopramide 10 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "10-20 mg IV over 15 min; pretreat with diphenhydramine 25 mg IV to prevent akathisia",
            "orderSentence": "Metoclopramide 10 mg IV"
          },
          "contraindications": "Parkinson's disease; tardive dyskinesia history; bowel obstruction; pheochromocytoma",
          "monitoring": "Akathisia, dystonia; discontinue if EPS",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "-"
        },
        {
          "item": "Prochlorperazine",
          "route": "IV",
          "indication": "Dopamine antagonist for acute migraine with prominent nausea",
          "dosing": {
            "doseOptions": [
              {
                "text": "10 mg",
                "orderSentence": "Prochlorperazine 10 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "10 mg IV slowly over 2 min; pretreat with diphenhydramine 25 mg IV",
            "orderSentence": "Prochlorperazine 10 mg IV"
          },
          "contraindications": "QT prolongation (QTc >500ms); Parkinson's disease; neuroleptic malignant syndrome history",
          "monitoring": "QTc if baseline prolonged; EPS",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "-"
        },
        {
          "item": "Diphenhydramine",
          "route": "IV",
          "indication": "Prevent akathisia from dopamine antagonists; sedation",
          "dosing": {
            "doseOptions": [
              {
                "text": "25 mg",
                "orderSentence": "Diphenhydramine 25 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "25-50 mg IV given concurrently with dopamine antagonist",
            "orderSentence": "Diphenhydramine 25 mg IV"
          },
          "contraindications": "Narrow-angle glaucoma; urinary retention; severe prostatic hypertrophy",
          "monitoring": "Sedation; anticholinergic effects",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "-"
        },
        {
          "item": "Magnesium sulfate",
          "route": "IV",
          "indication": "Migraine with aura - particularly effective; refractory migraine",
          "dosing": {
            "doseOptions": [
              {
                "text": "2 g",
                "orderSentence": "Magnesium sulfate 2 g IV"
              }
            ],
            "route": "IV",
            "instructions": "2 g IV in 50 mL NS over 20-30 min; may repeat x1 after 2 hr",
            "orderSentence": "Magnesium sulfate 2 g IV"
          },
          "contraindications": "Heart block; severe hypermagnesemia; myasthenia gravis; severe renal impairment",
          "monitoring": "BP, HR during infusion; flushing is common and benign",
          "ED": "STAT",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "-"
        },
        {
          "item": "Sumatriptan",
          "route": "SC/PO",
          "indication": "Acute migraine with TYPICAL aura (visual, sensory, language) - SAFE",
          "dosing": {
            "doseOptions": [
              {
                "text": "6 mg",
                "orderSentence": "Sumatriptan 6 mg SC"
              }
            ],
            "route": "SC",
            "instructions": "6 mg SC (may repeat after 1 hr, max 12 mg/24hr) OR 50-100 mg PO (may repeat after 2 hr, max 200 mg/24hr); take AFTER aura resolves or at headache onset",
            "orderSentence": "Sumatriptan 6 mg SC"
          },
          "contraindications": "**HEMIPLEGIC MIGRAINE (motor aura)**; uncontrolled HTN; CAD; prior stroke/TIA; MAOIs within 14 days; ergots within 24 hr",
          "monitoring": "Chest tightness (triptan sensation vs cardiac); assess cardiovascular risk",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Valproate sodium",
          "route": "IV",
          "indication": "Status migrainosus with aura; refractory to first-line",
          "dosing": {
            "doseOptions": [
              {
                "text": "500 mg",
                "orderSentence": "Valproate sodium 500 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "500-1000 mg IV over 5-10 min; may repeat 500 mg in 8 hr",
            "orderSentence": "Valproate sodium 500 mg IV"
          },
          "contraindications": "Hepatic disease; pregnancy (teratogenic); urea cycle disorders; pancreatitis history",
          "monitoring": "LFTs; ammonia if altered mental status",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "-"
        },
        {
          "item": "Dexamethasone",
          "route": "IV",
          "indication": "Prevent headache recurrence after acute treatment",
          "dosing": {
            "doseOptions": [
              {
                "text": "10 mg",
                "orderSentence": "Dexamethasone 10 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "10 mg IV x1 at time of discharge or admission; single dose",
            "orderSentence": "Dexamethasone 10 mg IV"
          },
          "contraindications": "Active untreated infection; known hypersensitivity",
          "monitoring": "Glucose if diabetic",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "-"
        }
      ],
      "Symptomatic Treatments": [
        {
          "item": "Rizatriptan",
          "route": "PO",
          "indication": "Acute typical migraine with aura; fast onset",
          "dosing": {
            "doseOptions": [
              {
                "text": "10 mg",
                "orderSentence": "Rizatriptan 10 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "5-10 mg PO (use 5 mg if on propranolol); may repeat after 2 hr; max 30 mg/24hr",
            "orderSentence": "Rizatriptan 10 mg PO"
          },
          "contraindications": "**HEMIPLEGIC MIGRAINE (motor aura)**; uncontrolled HTN; CAD; prior stroke/TIA; MAOIs within 14 days; ergots within 24 hr; use 5 mg max if on propranolol",
          "monitoring": "Triptan sensation",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Eletriptan",
          "route": "PO",
          "indication": "Acute typical migraine with aura; good for recurrence",
          "dosing": {
            "doseOptions": [
              {
                "text": "40 mg",
                "orderSentence": "Eletriptan 40 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "40 mg PO; may repeat 40 mg after 2 hr if partial response; max 80 mg/24hr",
            "orderSentence": "Eletriptan 40 mg PO"
          },
          "contraindications": "**HEMIPLEGIC MIGRAINE (motor aura)**; uncontrolled HTN; CAD; prior stroke/TIA; MAOIs within 14 days; ergots within 24 hr; potent CYP3A4 inhibitors (ketoconazole, clarithromycin)",
          "monitoring": "Triptan sensation",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Naratriptan",
          "route": "PO",
          "indication": "Migraine with aura; longer duration; menstrual migraine",
          "dosing": {
            "doseOptions": [
              {
                "text": "2.5 mg",
                "orderSentence": "Naratriptan 2.5 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "2.5 mg PO; may repeat after 4 hr; max 5 mg/24hr; slower onset but longer lasting",
            "orderSentence": "Naratriptan 2.5 mg PO"
          },
          "contraindications": "**HEMIPLEGIC MIGRAINE (motor aura)**; uncontrolled HTN; CAD; prior stroke/TIA; MAOIs within 14 days; ergots within 24 hr; moderate-severe renal/hepatic impairment",
          "monitoring": "Triptan sensation",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Ubrogepant",
          "route": "PO",
          "indication": "CGRP antagonist; use if triptan contraindicated or cardiovascular risk",
          "dosing": {
            "doseOptions": [
              {
                "text": "50 mg",
                "orderSentence": "Ubrogepant 50 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "50-100 mg PO; may repeat after 2 hr; max 200 mg/24hr",
            "orderSentence": "Ubrogepant 50 mg PO"
          },
          "contraindications": "Strong CYP3A4 inhibitors; severe hepatic impairment",
          "monitoring": "None routine; no cardiovascular contraindications",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Rimegepant",
          "route": "PO/ODT",
          "indication": "CGRP antagonist; can use for acute and prevention",
          "dosing": {
            "doseOptions": [
              {
                "text": "75 mg",
                "orderSentence": "Rimegepant 75 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "75 mg ODT at onset; max 75 mg/24hr for acute; also approved 75 mg every other day for prevention",
            "orderSentence": "Rimegepant 75 mg PO"
          },
          "contraindications": "Strong CYP3A4 inhibitors/inducers; severe hepatic impairment",
          "monitoring": "None routine",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Lasmiditan",
          "route": "PO",
          "indication": "5-HT1F agonist; safe in cardiovascular disease; ditan class",
          "dosing": {
            "doseOptions": [
              {
                "text": "100 mg",
                "orderSentence": "Lasmiditan 100 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "50-200 mg PO x1; max 200 mg/24hr; DO NOT DRIVE for 8 hours after dose",
            "orderSentence": "Lasmiditan 100 mg PO"
          },
          "contraindications": "Concurrent alcohol; CYP3A4 substrates with narrow TI",
          "monitoring": "CNS depression; dizziness; NO driving for 8 hr",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Ibuprofen",
          "route": "PO",
          "indication": "Mild-moderate aura migraine",
          "dosing": {
            "doseOptions": [
              {
                "text": "400 mg",
                "orderSentence": "Ibuprofen 400 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "400-800 mg PO at onset; max 2400 mg/day",
            "orderSentence": "Ibuprofen 400 mg PO"
          },
          "contraindications": "Renal impairment; active GI bleed; aspirin/NSAID allergy; third trimester",
          "monitoring": "GI symptoms; renal function if prolonged use",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Naproxen sodium",
          "route": "PO",
          "indication": "Mild-moderate aura migraine; menstrual migraine prevention",
          "dosing": {
            "doseOptions": [
              {
                "text": "550 mg",
                "orderSentence": "Naproxen sodium 550 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "550 mg PO at onset; may add 275 mg in 12 hr; max 1375 mg day 1, then 1100 mg/day",
            "orderSentence": "Naproxen sodium 550 mg PO"
          },
          "contraindications": "Renal impairment; active GI bleed; aspirin/NSAID allergy",
          "monitoring": "GI symptoms",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Acetaminophen-Aspirin-Caffeine",
          "route": "PO",
          "indication": "Mild-moderate migraine with aura (OTC option)",
          "dosing": {
            "doseOptions": [
              {
                "text": "2 tablets",
                "orderSentence": "Acetaminophen-Aspirin-Caffeine 2 tablets PO"
              }
            ],
            "route": "PO",
            "instructions": "2 tablets (250/250/65 mg each) at onset; max 2 doses/24hr",
            "orderSentence": "Acetaminophen-Aspirin-Caffeine 2 tablets PO"
          },
          "contraindications": "Aspirin allergy; hepatic impairment; avoid if using other acetaminophen sources",
          "monitoring": "Limit total acetaminophen <3 g/day",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Ondansetron",
          "route": "IV/PO",
          "indication": "Nausea/vomiting with migraine",
          "dosing": {
            "doseOptions": [
              {
                "text": "4 mg",
                "orderSentence": "Ondansetron 4 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "4 mg IV or 8 mg PO/ODT; may repeat q8h as needed",
            "orderSentence": "Ondansetron 4 mg IV"
          },
          "contraindications": "QT prolongation (QTc >500ms); severe hepatic impairment",
          "monitoring": "QTc if multiple doses or baseline prolongation",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Second-line/Refractory": [
        {
          "item": "Dihydroergotamine (DHE)",
          "route": "IV/SC/Nasal",
          "indication": "Refractory migraine; status migrainosus; **NOT for hemiplegic**",
          "dosing": {
            "doseOptions": [
              {
                "text": "0.5 mg",
                "orderSentence": "Dihydroergotamine (DHE) 0.5 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "IV: 0.5-1 mg q8h for up to 3 days (pretreat with antiemetic); SC: 1 mg, may repeat in 1 hr; Nasal: 1 spray each nostril, repeat in 15 min",
            "orderSentence": "Dihydroergotamine (DHE) 0.5 mg IV"
          },
          "contraindications": "Pregnancy; CAD; uncontrolled HTN; peripheral vascular disease; **HEMIPLEGIC MIGRAINE**; triptan use within 24hr; severe hepatic/renal impairment",
          "monitoring": "BP; nausea; chest pain; continuous cardiac monitoring for IV",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Occipital nerve block",
          "route": "SC",
          "indication": "Refractory migraine; occipital-predominant pain",
          "dosing": {
            "doseOptions": [
              {
                "text": "2.5 mL",
                "orderSentence": "Occipital nerve block 2.5 mL SC"
              }
            ],
            "route": "SC",
            "instructions": "Inject bupivacaine 0.5% 2-3 mL + triamcinolone 40 mg at greater occipital nerve bilaterally; may add lesser occipital, supraorbital",
            "orderSentence": "Occipital nerve block 2.5 mL SC"
          },
          "contraindications": "Local anesthetic allergy; infection at injection site; anticoagulation (relative)",
          "monitoring": "Vasovagal reaction; immediate pain assessment",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Ketamine",
          "route": "IV",
          "indication": "Status migrainosus refractory to DHE",
          "dosing": {
            "doseOptions": [
              {
                "text": "0.1 mg/kg/hr",
                "orderSentence": "Ketamine 0.1 mg/kg/hr IV"
              }
            ],
            "route": "IV",
            "instructions": "0.1-0.3 mg/kg/hr continuous infusion for 24-48 hr; subanesthetic dosing only",
            "orderSentence": "Ketamine 0.1 mg/kg/hr IV"
          },
          "contraindications": "Uncontrolled HTN; psychosis history; elevated ICP; pregnancy",
          "monitoring": "Dissociation; BP; HR; requires continuous cardiac monitoring",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "-",
          "ICU": "-"
        },
        {
          "item": "Verapamil",
          "route": "IV",
          "indication": "Hemiplegic migraine acute (if severe); status migrainosus",
          "dosing": {
            "doseOptions": [
              {
                "text": "5 mg",
                "orderSentence": "Verapamil 5 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "5 mg IV over 2-3 min; may repeat in 30 min (max 20 mg)",
            "orderSentence": "Verapamil 5 mg IV"
          },
          "contraindications": "Heart block (2nd/3rd degree); severe LV dysfunction; hypotension",
          "monitoring": "Continuous ECG; BP; for hemiplegic migraine when triptans contraindicated",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "-",
          "ICU": "-"
        },
        {
          "item": "Intranasal lidocaine",
          "route": "Intranasal",
          "indication": "Acute migraine with aura; rapid onset option",
          "dosing": {
            "doseOptions": [
              {
                "text": "0.5 mL",
                "orderSentence": "Intranasal lidocaine 0.5 mL Intranasal"
              }
            ],
            "route": "Intranasal",
            "instructions": "4% lidocaine 0.5 mL per nostril directed at sphenopalatine fossa; may repeat x1 in 15 min",
            "orderSentence": "Intranasal lidocaine 0.5 mL Intranasal"
          },
          "contraindications": "Local anesthetic allergy",
          "monitoring": "Local numbness; cardiac arrhythmia (rare with low dose)",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Disease-Modifying or Chronic Therapies (Preventive Medications)": [
        {
          "item": "Magnesium oxide",
          "route": "PO",
          "indication": "First-line supplement for migraine with aura prevention",
          "dosing": {
            "doseOptions": [
              {
                "text": "400 mg",
                "orderSentence": "Magnesium oxide 400 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 400 mg daily; may increase to 400 mg BID; take with food to reduce GI upset",
            "orderSentence": "Magnesium oxide 400 mg PO"
          },
          "pretreatment": "None",
          "contraindications": "Renal impairment (CrCl <30) - dose reduce",
          "monitoring": "Diarrhea; check Mg level if symptomatic or renal disease",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Topiramate",
          "route": "PO",
          "indication": "First-line oral prevention; reduces aura frequency; weight loss",
          "dosing": {
            "doseOptions": [
              {
                "text": "25 mg",
                "orderSentence": "Topiramate 25 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 25 mg qHS; increase by 25 mg/wk; target 50-100 mg BID",
            "orderSentence": "Topiramate 25 mg PO"
          },
          "pretreatment": "None",
          "contraindications": "**PREGNANCY (teratogenic)**; glaucoma; kidney stones; metabolic acidosis",
          "monitoring": "Cognitive effects; paresthesias; weight; serum bicarbonate; kidney stones",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Propranolol",
          "route": "PO",
          "indication": "First-line prevention; comorbid HTN, anxiety, tremor",
          "dosing": {
            "doseOptions": [
              {
                "text": "40 mg",
                "orderSentence": "Propranolol 40 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 40 mg BID or 80 mg LA daily; titrate q2wk; target 80-240 mg/day",
            "orderSentence": "Propranolol 40 mg PO"
          },
          "pretreatment": "None",
          "contraindications": "Asthma; COPD with bronchospasm; bradycardia <50; 2nd/3rd degree heart block; decompensated HF",
          "monitoring": "HR (goal >50); BP; fatigue; depression; exercise intolerance",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Amitriptyline",
          "route": "PO",
          "indication": "Prevention with comorbid insomnia, depression, tension-type headache",
          "dosing": {
            "doseOptions": [
              {
                "text": "10 mg",
                "orderSentence": "Amitriptyline 10 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 10 mg qHS; titrate by 10-25 mg q1-2wk; target 25-75 mg qHS",
            "orderSentence": "Amitriptyline 10 mg PO"
          },
          "pretreatment": "ECG if >50 y/o or cardiac history",
          "contraindications": "Cardiac conduction disease; recent MI; glaucoma; urinary retention; elderly (anticholinergic burden)",
          "monitoring": "Sedation; weight; dry mouth; ECG if dose >100 mg or cardiac history",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Venlafaxine XR",
          "route": "PO",
          "indication": "Prevention with comorbid depression, anxiety",
          "dosing": {
            "doseOptions": [
              {
                "text": "37.5 mg",
                "orderSentence": "Venlafaxine XR 37.5 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 37.5 mg daily; increase by 37.5-75 mg q1wk; target 75-150 mg daily",
            "orderSentence": "Venlafaxine XR 37.5 mg PO"
          },
          "pretreatment": "None",
          "contraindications": "Uncontrolled HTN; MAOIs within 14 days; abrupt discontinuation risk",
          "monitoring": "BP at doses >150 mg; serotonin syndrome signs; taper to discontinue",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Candesartan",
          "route": "PO",
          "indication": "Prevention; comorbid HTN; beta-blocker intolerant",
          "dosing": {
            "doseOptions": [
              {
                "text": "8 mg",
                "orderSentence": "Candesartan 8 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 8 mg daily; may increase to 16 mg daily after 4 wk",
            "orderSentence": "Candesartan 8 mg PO"
          },
          "pretreatment": "None",
          "contraindications": "**Pregnancy**; bilateral renal artery stenosis; hyperkalemia",
          "monitoring": "BP; potassium; creatinine",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Valproate/Divalproex",
          "route": "PO",
          "indication": "Prevention with comorbid bipolar or epilepsy",
          "dosing": {
            "doseOptions": [
              {
                "text": "250 mg",
                "orderSentence": "Valproate/Divalproex 250 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 250 mg BID or 500 mg ER daily; titrate to 500-1000 mg/day",
            "orderSentence": "Valproate/Divalproex 250 mg PO"
          },
          "pretreatment": "LFTs; CBC",
          "contraindications": "**Pregnancy (teratogenic - neural tube defects)**; hepatic disease; urea cycle disorders; pancreatitis history",
          "monitoring": "LFTs q6mo; weight; hair loss; tremor; CBC",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Riboflavin (Vitamin B2)",
          "route": "PO",
          "indication": "Supplement for prevention; well-tolerated; may reduce aura",
          "dosing": {
            "doseOptions": [
              {
                "text": "400 mg",
                "orderSentence": "Riboflavin (Vitamin B2) 400 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "400 mg daily",
            "orderSentence": "Riboflavin (Vitamin B2) 400 mg PO"
          },
          "pretreatment": "None",
          "contraindications": "None",
          "monitoring": "Fluorescent yellow urine (reassure patient); benign",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Coenzyme Q10",
          "route": "PO",
          "indication": "Supplement; mitochondrial support",
          "dosing": {
            "doseOptions": [
              {
                "text": "100 mg",
                "orderSentence": "Coenzyme Q10 100 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "100-300 mg daily",
            "orderSentence": "Coenzyme Q10 100 mg PO"
          },
          "pretreatment": "None",
          "contraindications": "None",
          "monitoring": "None",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Erenumab (Aimovig)",
          "route": "SC",
          "indication": "CGRP mAb; failed 2+ oral preventives or intolerance",
          "dosing": {
            "doseOptions": [
              {
                "text": "70 mg",
                "orderSentence": "Erenumab (Aimovig) 70 mg SC"
              }
            ],
            "route": "SC",
            "instructions": "70 mg SC monthly; may increase to 140 mg monthly after 3 months if suboptimal response",
            "orderSentence": "Erenumab (Aimovig) 70 mg SC"
          },
          "pretreatment": "None",
          "contraindications": "Hypersensitivity to erenumab",
          "monitoring": "Constipation (can be severe - may need laxatives); injection site reactions; HTN monitoring",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Fremanezumab (Ajovy)",
          "route": "SC",
          "indication": "CGRP mAb; flexible dosing options",
          "dosing": {
            "doseOptions": [
              {
                "text": "225 mg",
                "orderSentence": "Fremanezumab (Ajovy) 225 mg SC"
              }
            ],
            "route": "SC",
            "instructions": "225 mg SC monthly OR 675 mg SC quarterly (three 225 mg injections)",
            "orderSentence": "Fremanezumab (Ajovy) 225 mg SC"
          },
          "pretreatment": "None",
          "contraindications": "Hypersensitivity",
          "monitoring": "Injection site reactions",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Galcanezumab (Emgality)",
          "route": "SC",
          "indication": "CGRP mAb; requires loading dose",
          "dosing": {
            "doseOptions": [
              {
                "text": "240 mg",
                "orderSentence": "Galcanezumab (Emgality) 240 mg SC"
              }
            ],
            "route": "SC",
            "instructions": "240 mg SC loading dose (2 x 120 mg injections), then 120 mg SC monthly",
            "orderSentence": "Galcanezumab (Emgality) 240 mg SC"
          },
          "pretreatment": "None",
          "contraindications": "Hypersensitivity",
          "monitoring": "Injection site reactions; vertigo",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Onabotulinumtoxin A (Botox)",
          "route": "IM",
          "indication": "Chronic migraine with aura (≥15 days/month); failed oral preventives",
          "dosing": {
            "doseOptions": [
              {
                "text": "155 units",
                "orderSentence": "Onabotulinumtoxin A (Botox) 155 units IM"
              }
            ],
            "route": "IM",
            "instructions": "155-195 units across 31-39 injection sites per PREEMPT protocol; repeat q12 weeks; effect may take 2-3 cycles",
            "orderSentence": "Onabotulinumtoxin A (Botox) 155 units IM"
          },
          "pretreatment": "None",
          "contraindications": "Infection at injection sites; myasthenia gravis; neuromuscular disorder",
          "monitoring": "Neck weakness; ptosis; antibody formation if loss of effect",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Flunarizine",
          "route": "PO",
          "indication": "Calcium channel blocker for prevention; especially hemiplegic migraine",
          "dosing": {
            "doseOptions": [
              {
                "text": "5 mg",
                "orderSentence": "Flunarizine 5 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 5 mg qHS; may increase to 10 mg qHS; especially useful for hemiplegic migraine (not available in US)",
            "orderSentence": "Flunarizine 5 mg PO"
          },
          "pretreatment": "None",
          "contraindications": "Depression; Parkinson's disease; extrapyramidal disorders",
          "monitoring": "Weight gain; depression; parkinsonism with prolonged use",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Lamotrigine",
          "route": "PO",
          "indication": "May reduce aura frequency specifically; hemiplegic migraine",
          "dosing": {
            "doseOptions": [
              {
                "text": "25 mg",
                "orderSentence": "Lamotrigine 25 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 25 mg daily; increase by 25 mg q2wk to 50-100 mg BID; SLOW titration to prevent rash",
            "orderSentence": "Lamotrigine 25 mg PO"
          },
          "pretreatment": "None",
          "contraindications": "History of lamotrigine-related rash; interacting drugs (valproate halves dose)",
          "monitoring": "**RASH (stop immediately if rash develops - SJS risk)**; monitor closely during titration",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Acetazolamide",
          "route": "PO",
          "indication": "Hemiplegic migraine prevention; familial hemiplegic migraine",
          "dosing": {
            "doseOptions": [
              {
                "text": "250 mg",
                "orderSentence": "Acetazolamide 250 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 250 mg BID; may increase to 500 mg BID",
            "orderSentence": "Acetazolamide 250 mg PO"
          },
          "pretreatment": "None",
          "contraindications": "Sulfa allergy; severe hepatic/renal disease; hypokalemia; acidosis",
          "monitoring": "Paresthesias; metabolic acidosis; K+; bicarbonate",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ]
    },
    "Other Recommendations": {
      "Referrals & Consults": [
        {
          "item": "Neurology/Headache specialist referral for aura characterization, preventive optimization, and differentiation from other neurological conditions",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "OB/GYN consultation for contraceptive counseling - **estrogen-containing contraceptives contraindicated** in migraine with aura due to elevated ischemic stroke risk",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Cardiology referral if TTE shows PFO for discussion of closure in select cases (recurrent cryptogenic stroke or debilitating aura despite medical therapy)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Genetics consultation if hemiplegic migraine suspected for CACNA1A, ATP1A2, SCN1A testing and family counseling",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Physical therapy for cervicogenic component and trigger point management",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Psychology/Behavioral medicine for CBT addressing aura anxiety, attack anticipation, and comorbid mood disorders",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Ophthalmology if visual aura atypical or concern for retinal pathology",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Sleep medicine if sleep disorder contributing to migraine frequency (OSA, insomnia)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Patient Instructions": [
        {
          "item": "Return immediately for new/different headache, \"worst headache of life,\" or thunderclap onset which may indicate subarachnoid hemorrhage",
          "ED": "STAT",
          "HOSP": "-",
          "OPD": "ROUTINE"
        },
        {
          "item": "Return immediately if aura persists >60 minutes or if new weakness on one side of body develops (need to rule out stroke)",
          "ED": "STAT",
          "HOSP": "-",
          "OPD": "ROUTINE"
        },
        {
          "item": "Return immediately for headache with fever, stiff neck, or altered mental status which may indicate CNS infection",
          "ED": "STAT",
          "HOSP": "-",
          "OPD": "ROUTINE"
        },
        {
          "item": "**AVOID estrogen-containing contraceptives** (combined birth control pills, patch, ring) - use progestin-only methods (mini-pill, Depo-Provera, Mirena IUD, Nexplanon) or non-hormonal methods",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Triptans ARE safe for your typical visual/sensory aura - take at headache onset or when aura ends; do NOT take if you experience weakness (motor aura)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Maintain headache/aura diary tracking aura type, duration, triggers, and medication use to guide treatment optimization",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Limit acute medication use to ≤10 days/month to prevent medication overuse headache which worsens both headache and aura",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Learn your personal aura warning signs and take acute medication promptly when headache begins",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Do not drive or operate machinery during visual or motor aura as vision and coordination may be impaired",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        }
      ],
      "Lifestyle & Prevention": [
        {
          "item": "Regular sleep schedule (7-8 hours, consistent bedtime) as sleep changes are a major aura trigger",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Avoid known aura triggers (bright/flashing lights, high altitude, significant sleep deprivation, extreme stress)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Regular aerobic exercise (30 min moderate activity 5x/week) reduces migraine frequency; avoid if currently in aura",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Magnesium-rich diet (leafy greens, nuts, whole grains) or supplementation as magnesium specifically helps aura",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Stress management techniques (mindfulness, biofeedback, relaxation training) as stress is a major trigger",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Adequate hydration (at least 64 oz water daily) as dehydration can trigger attacks",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Smoking cessation to reduce vascular risk, particularly important given aura-associated stroke risk",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Caffeine moderation (≤200 mg/day) and consistent daily intake to avoid withdrawal triggers",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Blood pressure control (target <130/80) given elevated vascular risk with aura",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE"
        },
        {
          "item": "Avoid high altitude or rapid altitude changes if altitude is a known aura trigger",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE"
        }
      ]
    }
  },
  "differential": [
    {
      "diagnosis": "Transient ischemic attack (TIA)",
      "features": "Sudden onset (maximal at onset vs gradual aura spread); negative symptoms (vision loss vs positive scintillations); vascular risk factors; older age; duration usually <1 hr",
      "tests": "MRI DWI (no restriction in aura); MRA/CTA (no vessel occlusion); aura has visual \"march\""
    },
    {
      "diagnosis": "Ischemic stroke",
      "features": "Fixed deficit; sudden onset; vascular territory distribution; risk factors",
      "tests": "MRI DWI (shows restriction); CT may be normal early"
    },
    {
      "diagnosis": "Migraine with brainstem aura",
      "features": "Aura includes brainstem symptoms (vertigo, tinnitus, decreased hearing, diplopia, ataxia, dysarthria, decreased LOC)",
      "tests": "Clinical criteria; MRI to exclude posterior fossa lesion"
    },
    {
      "diagnosis": "Retinal migraine",
      "features": "Monocular visual symptoms (vs binocular in typical aura); complete vision loss in one eye",
      "tests": "Ophthalmology exam; cover/uncover test during symptoms"
    },
    {
      "diagnosis": "Focal seizure with visual phenomena",
      "features": "Shorter duration (seconds to minutes); positive phenomena; may have automatisms; post-ictal confusion",
      "tests": "EEG may show epileptiform activity; MRI for structural lesion"
    },
    {
      "diagnosis": "Transient global amnesia",
      "features": "Anterograde amnesia; repetitive questioning; no visual or motor symptoms; resolves <24 hr",
      "tests": "Clinical diagnosis; MRI may show hippocampal DWI changes"
    },
    {
      "diagnosis": "Giant cell arteritis",
      "features": "Age >50; scalp tenderness; jaw claudication; visual loss (not scintillations); elevated ESR/CRP",
      "tests": "ESR, CRP (elevated); temporal artery biopsy"
    },
    {
      "diagnosis": "Carotid/vertebral dissection",
      "features": "Neck pain; Horner syndrome; pulsatile tinnitus; stroke symptoms",
      "tests": "MRA/CTA neck showing dissection"
    },
    {
      "diagnosis": "CADASIL",
      "features": "Migraine with aura often first symptom; subcortical strokes; family history; cognitive decline",
      "tests": "MRI shows characteristic WMH (anterior temporal, external capsule); NOTCH3 mutation"
    },
    {
      "diagnosis": "Mitochondrial encephalopathy (MELAS)",
      "features": "Stroke-like episodes not following vascular territory; seizures; elevated lactate; short stature",
      "tests": "MRI (non-vascular stroke pattern); genetic testing; muscle biopsy"
    }
  ],
  "evidence": [
    {
      "recommendation": "Migraine with aura increases ischemic stroke risk, especially in women using combined oral contraceptives",
      "evidenceLevel": "Class II, Level B",
      "source": "[Etminan et al. BMJ 2005](https://pubmed.ncbi.nlm.nih.gov/15647264/)"
    },
    {
      "recommendation": "ACOG: Combined hormonal contraceptives contraindicated in migraine with aura",
      "evidenceLevel": "Class I (Guideline)",
      "source": "[ACOG Practice Bulletin 2019](https://pubmed.ncbi.nlm.nih.gov/31568397/)"
    },
    {
      "recommendation": "Triptans safe and effective in migraine with typical aura",
      "evidenceLevel": "Class I, Level A",
      "source": "[Marmura et al. Headache 2015](https://pubmed.ncbi.nlm.nih.gov/25600718/)"
    },
    {
      "recommendation": "Triptans contraindicated in hemiplegic migraine (expert consensus)",
      "evidenceLevel": "Class III, Level C",
      "source": "Expert consensus; [IHS Classification ICHD-3 2018](https://pubmed.ncbi.nlm.nih.gov/29368949/)"
    },
    {
      "recommendation": "Magnesium particularly effective for migraine with aura prevention",
      "evidenceLevel": "Class II, Level B",
      "source": "[Peikert et al. Cephalalgia 1996](https://pubmed.ncbi.nlm.nih.gov/8792038/)"
    },
    {
      "recommendation": "Lamotrigine may reduce aura frequency specifically",
      "evidenceLevel": "Class II, Level C",
      "source": "[Lampl et al. Neurology 2005](https://pubmed.ncbi.nlm.nih.gov/16087905/)"
    },
    {
      "recommendation": "Topiramate effective for migraine prevention",
      "evidenceLevel": "Class I, Level A",
      "source": "[Silberstein et al. Arch Neurol 2004](https://pubmed.ncbi.nlm.nih.gov/15096395/)"
    },
    {
      "recommendation": "Propranolol effective for migraine prevention",
      "evidenceLevel": "Class I, Level A",
      "source": "[Linde et al. Cochrane 2004](https://pubmed.ncbi.nlm.nih.gov/15106218/)"
    },
    {
      "recommendation": "CGRP monoclonal antibodies effective for prevention",
      "evidenceLevel": "Class I, Level A",
      "source": "[Goadsby et al. NEJM 2017 (erenumab STRIVE)](https://pubmed.ncbi.nlm.nih.gov/29171821/)"
    },
    {
      "recommendation": "Gepants safe in patients with cardiovascular contraindications to triptans",
      "evidenceLevel": "Class I, Level B",
      "source": "[Dodick et al. JAMA 2019 (ubrogepant ACHIEVE I)](https://pubmed.ncbi.nlm.nih.gov/31742631/)"
    },
    {
      "recommendation": "Lasmiditan (ditan) does not have cardiovascular contraindications",
      "evidenceLevel": "Class I, Level A",
      "source": "[Kuca et al. Headache 2018](https://pubmed.ncbi.nlm.nih.gov/30091160/)"
    },
    {
      "recommendation": "IV magnesium effective for acute migraine with aura",
      "evidenceLevel": "Class II, Level B",
      "source": "[Bigal et al. Headache 2002](https://pubmed.ncbi.nlm.nih.gov/11903546/)"
    },
    {
      "recommendation": "Aura duration >60 minutes warrants stroke evaluation",
      "evidenceLevel": "Class III, Level C",
      "source": "Expert consensus; [Lipton et al. Headache 2004](https://pubmed.ncbi.nlm.nih.gov/15147249/)"
    },
    {
      "recommendation": "PFO closure may benefit select patients with migraine with aura",
      "evidenceLevel": "Class II, Level B",
      "source": "[Tobis et al. JACC 2017 (RESPECT trial long-term)](https://pubmed.ncbi.nlm.nih.gov/28359515/)"
    },
    {
      "recommendation": "Acetazolamide effective for familial hemiplegic migraine",
      "evidenceLevel": "Class III, Level C",
      "source": "[Battistini et al. Neurology 1999](https://pubmed.ncbi.nlm.nih.gov/10489058/)"
    },
    {
      "recommendation": "Verapamil may be used acutely in hemiplegic migraine",
      "evidenceLevel": "Class III, Level C",
      "source": "Expert consensus; [Mathew et al. Headache 2005](https://pubmed.ncbi.nlm.nih.gov/15836583/)"
    },
    {
      "recommendation": "OnabotulinumtoxinA effective for chronic migraine",
      "evidenceLevel": "Class I, Level A",
      "source": "[Dodick et al. Headache 2010 (PREEMPT pooled)](https://pubmed.ncbi.nlm.nih.gov/20487038/)"
    },
    {
      "recommendation": "Exercise as effective as topiramate for migraine prevention",
      "evidenceLevel": "Class II, Level B",
      "source": "[Varkey et al. Cephalalgia 2011](https://pubmed.ncbi.nlm.nih.gov/21816772/)"
    }
  ],
  "monitoring": [
    {
      "item": "Aura characteristics (type, duration, frequency)",
      "frequency": "Each visit; diary",
      "action": "Prolonged aura needs stroke rule-out; increasing frequency reassess prevention",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Headache days/month",
      "frequency": "Monthly",
      "action": "Escalate therapy if not meeting target; consider CGRP mAb or Botox",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Acute medication use days",
      "frequency": "Monthly",
      "action": "MOH education; consider preventive escalation; may need withdrawal",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Blood pressure",
      "frequency": "Each visit",
      "action": "Optimize BP control given elevated vascular risk with aura",
      "ED": "STAT",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "HIT-6 or MIDAS disability score",
      "frequency": "Every 3 months",
      "action": "Escalate preventive therapy if severely disabled",
      "ED": "-",
      "HOSP": "-",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Topiramate: serum bicarbonate",
      "frequency": "Baseline, 3 months",
      "action": "Consider dose reduction or switch if metabolic acidosis",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Valproate: LFTs",
      "frequency": "Baseline, 3 months, then q6mo",
      "action": "Discontinue if significant elevation",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "CGRP mAb: constipation assessment",
      "frequency": "Each visit",
      "action": "Add fiber/laxatives; reduce dose or discontinue if severe",
      "ED": "-",
      "HOSP": "-",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Lamotrigine: rash monitoring",
      "frequency": "Weekly during titration",
      "action": "**STOP IMMEDIATELY if rash develops** - SJS risk",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Contraceptive status",
      "frequency": "Each visit (women of reproductive age)",
      "action": "Remove estrogen-containing contraceptives; counsel on alternatives",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    }
  ],
  "disposition": [
    {
      "disposition": "Discharge home",
      "criteria": "Typical aura pattern confirmed; no stroke symptoms; pain controlled; able to tolerate PO; follow-up arranged; contraceptive counseling if needed"
    },
    {
      "disposition": "Admit to floor",
      "criteria": "Prolonged aura (>60 min) requiring observation; status migrainosus requiring IV therapy; first aura with abnormal imaging requiring further workup; hemiplegic migraine with prolonged weakness"
    },
    {
      "disposition": "Admit to ICU",
      "criteria": "Migrainous infarction (stroke occurring during typical aura); hemodynamic instability; severe refractory status migrainosus requiring ketamine infusion"
    },
    {
      "disposition": "Transfer to higher level",
      "criteria": "Stroke mimicking aura requiring thrombectomy evaluation; complex hemiplegic migraine requiring tertiary headache center"
    },
    {
      "disposition": "Outpatient follow-up",
      "criteria": "New diagnosis: 2-4 weeks; Stable on prevention: 3-6 months; After preventive change: 4-8 weeks"
    }
  ]
}